Speaker Biography

Qingyong Ma
Biography:

Qingyong Ma has completed his PhD from Queen’s University of Belfast during 1992 to 1996. He is the professor and head of Department of Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi’an, China. He has his expertise in pancreatitis and pancreatic cancer. He has published more than 100 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract:

Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescribed medications for type 2 diabetes mellitus. However, its role in pancreatic cancer is not fully elucidated. Herein, we aimed to further study the preventive and therapeutic effects of metformin in genetically engineered mouse models of pancreatic cancer. We treated KrasLSL-G12D/+; Pdx1-Cre (KC) mice with vehicle or metformin for 4 weeks. Chronic pancreatitis was induced by peritoneal injection of cerulein. KrasLSL-G12D/+; Trp53fl/+; Pdx1-Cre (KPC) mice were used to investigate the therapeutic efficiency of metformin. We found that following metformin treatment, acinar-to-ductal metaplasia (ADM) and mouse pancreatic intraepithelial neoplasia (mPanIN) were decreased in KC mice. Chronic pancreatitis induced a stroma-rich and duct-like structure and increased the formation of ADM and mPanIN lesions, in line with an increased cytokeratin 19 (CK19)-stained area. Metformin treatment diminished chronic pancreatitis-mediated ADM and mPanIN formation. In addition, it alleviated the percent area of Masson’s trichrome staining. In KPC mice, metformin impaired tumor growth and decreased the incidence of abdominal invasion. More importantly, it prolonged the overall survival. In conclusion, we demonstrate that metformin shows promising effects in the prevention of pancreatic tumorigenesis and pancreatic cancer progression.